Sleep Apnea News and Research

RSS

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

From ResMed Corp 21 May 2012

Primary care-based management can reduce burden of OSA

Patients with moderate-to-severe obstructive sleep apnea (OSA) can be successfully managed in a primary care setting by appropriately trained primary care physicians (PCPs) and community-based nurses, according to Australian researchers.

21 May 2012

Treatment of OSA in children can reverse neuronal brain injury

Treatment of obstructive sleep apnea (OSA) in children normalizes disturbances in the neuronal network responsible for attention and executive function, according to a new study.

21 May 2012

Sleep-disordered breathing may increase risk of cancer mortality

Sleep-disordered breathing (SDB), commonly known as sleep apnea, is associated with an increased risk of cancer mortality, according to a new study.

21 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.

7 May 2012

Regular jogging increases life expectancy

Undertaking regular jogging increases the life expectancy of men by 6.2 years and women by 5.6 years, reveals the latest data from the Copenhagen City Heart study presented at the EuroPRevent2012 meeting.

4 May 2012

Excessive daytime sleepiness may cause learning, attention and behavior problems

Children who have learning, attention and behavior problems may be suffering from excessive daytime sleepiness, even though clinical tests show them sleeping long enough at night, a new study reports.

2 May 2012

HealthClips Rx patient education app now available in iTunes

Milner-Fenwick, Inc. and Preventice, Inc. announced today that the HealthClips Rx patient education app is now available in iTunes. To familiarize health care providers with this interactive patient education model, Milner-Fenwick and Preventice are offering a free, two-week trial to physicians and care providers.

2 May 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

Enrollment complete for In-tunnel SeptRx European PFO Trial in Europe

SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO), reported today that it has completed enrollment for its "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

23 Apr 2012

A guide to catch and treat hypertension early in children

High blood pressure in children and adolescents is a growing health problem that is often overlooked by physicians, according to a University of Michigan Health System article published in American Family Physician that offers doctors a guide to catching and treating hypertension early.

18 Apr 2012

UVA engineer and biologist named recipients of Hartwell Individual Biomedical Research Awards

University of Virginia engineer Silvia Salinas Blemker and biologist Christopher Deppmann have been named recipients of 2011 Hartwell Individual Biomedical Research Awards, which provide $100,000 in annual research support for three years to each awardee.

16 Apr 2012

ASPO to hold pediatric otolaryngology meeting from April 18 - April 22

The American Society of Pediatric Otolaryngology (ASPO) will hold its annual meeting, April 18 - April 22, during the 2012 Combined Otolaryngology Spring Meetings (COSM) - a joint meeting of eight otolaryngological societies in San Diego, CA. The meeting will feature dozens of scientific presentations highlighting research in progress in the field of otolaryngology-head and neck surgery.

10 Apr 2012

Par Pharmaceutical commences shipment of modafinil tablets

Par Pharmaceutical Companies, Inc. today announced that it began shipping all strengths of modafinil tablets, a generic version of Teva's Provigil brand.

7 Apr 2012

Researchers understand TG paradox in people of African descent

In most people, high blood levels of the fat known as triglycerides are an early warning sign of type 2 diabetes and metabolic syndrome, but in people of African descent these dangerous health conditions may go undiagnosed because triglyceride levels are not at the level used to diagnose metabolic syndrome (>150 mg/dL). This is known as the "TG (or lipid) paradox."

6 Apr 2012